Post-approval studies (Phase 4)Not Yet RecruitingNCT07477132
What this trial is testing
A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old
Who this might be right for
Curarization, Postoperative Residual
University Hospital, Caen 99